[Form 4] BioCardia, Inc. Warrant Insider Trading Activity

Rhea-AI Filing Summary

Peter Altman, President, CEO and Director of BioCardia, Inc., purchased shares of the company’s common stock on 08/22/2025. The filing reports a total of 700 shares acquired in multiple trades at prices ranging from $1.82 to $1.89 per share, with a weighted average price of $1.83 reported. After the transaction, the reporting person beneficially owns 168,762 shares directly.

The Form 4 was submitted under power of attorney on 08/25/2025 and includes an undertaking to provide details of the separate trade prices upon request.

Insights

Financial Analyst

TL;DR: Insider purchased a small block of shares at ~$1.83, modest change to ownership.

The reported purchase of 700 shares at a weighted average of $1.83 is a routine insider transaction that slightly increases direct ownership to 168,762 shares. The dollar value of the purchase (~$1,281) is small relative to total holdings, so the transaction is unlikely to be material to valuation or cash flows. The filing’s disclosure that trades occurred across prices $1.82–$1.89 and the offer to provide per-trade details is appropriate for transparency.

Corporate Governance Expert

TL;DR: Disclosure complies with Section 16; transaction appears routine and properly reported.

The Form 4 identifies the reporting person’s roles and reports the purchase with a weighted-average price and an explanatory note about multiple trade prices, which aligns with reporting expectations. The signature by power of attorney is noted. There are no indications of protocol breaches or missing mandatory fields in the disclosed content.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CA 94085

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		P		700(1)	A	$1.83(1)	168,762	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $1.82 to $1.89 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the BioCardia (BCDAW) insider report?

The filing reports that Peter Altman purchased 700 shares of BioCardia common stock on 08/22/2025.

At what price were the shares purchased according to the Form 4?

Trades occurred between $1.82 and $1.89 per share; the filing reports a weighted average price of $1.83.

How many shares does the reporting person own after the transaction?

The reporting person beneficially owns 168,762 shares following the reported purchase.

What is the reporting person’s role at BioCardia?

The reporting person, Peter Altman, is identified as President and CEO and a Director of the issuer.

When was the Form 4 signed and filed?

The signature block shows the filing was signed by power of attorney on 08/25/2025.